Arriva Pharmaceuticals, Inc. v. Lezdey (In Re Arriva Pharmaceuticals, Inc.)

456 B.R. 419, 2011 WL 1577804
CourtUnited States Bankruptcy Court, N.D. California
DecidedApril 26, 2011
Docket19-40275
StatusPublished
Cited by2 cases

This text of 456 B.R. 419 (Arriva Pharmaceuticals, Inc. v. Lezdey (In Re Arriva Pharmaceuticals, Inc.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Arriva Pharmaceuticals, Inc. v. Lezdey (In Re Arriva Pharmaceuticals, Inc.), 456 B.R. 419, 2011 WL 1577804 (Cal. 2011).

Opinion

DECISION

EDWARD D. JELLEN, Bankruptcy Judge.

Plaintiff Arriva Pharmaceuticals, Inc., the above reorganized debtor (“Arriva”), has moved for summary judgment on its fourth claim for relief in this adversary proceeding against defendants John Lez-dey (“Lezdey”), J.L. Technology L.P., and Jamie Holding Company, LLC. 1 (The defendants herein are jointly hereinafter referred to as the “Lezdey Parties.”) The court will grant Arriva’s motion.

A. Background

This adversary proceeding is the latest installment of a dispute in which the litigation has spanned both the continent and three different decades. At the core of the dispute is a License Agreement (the “Protease License”) dated April 16, 1998 between Protease Sciences, Inc., as the li-censor (“PSI”), and Arriva, then known as AlphaOne Pharmaceuticals, Inc., as the licensee. By the Protease License, PSI granted Arriva an exclusive license of certain patents for drugs to treat respiratory diseases.

Following execution of the Protease License, Lezdey and several entities that Lezdey and members of his family controlled claimed that the Protease License was invalid, whereupon a series of lawsuits began, all of which ultimately affirmed the validity of the Protease License. 2

On August 29, 2007, Arriva filed a voluntary petition herein under chapter 11 of the Bankruptcy Code. On September 13, 2007, Arriva filed the required bankruptcy schedules and statements, including Schedule G (Executory Contracts), which listed the Protease License as one of the execu-tory contracts to which Arriva was a party at the date of its chapter 11 petition.

On December 12, 2007, Arriva filed its Fourth Amended Chapter 11 Plan of Reorganization (the “Plan”). Paragraph 8.1 of the Plan provided for Arriva to assume the *422 Protease License. See Bankruptcy Code §§ 365(a) and 1123(b)(2). 3

By order entered January 30, 2008 (the “Confirmation Order”), this court confirmed Arriva’s Plan. The Confirmation Order is final. 4 Under the terms of the Plan and the Confirmation Order, the Plan went into effect on February 13, 2008, on which date Arriva’s assumption of the Protease License became effective.

Thereafter, on September 3, 2009, the Lezdey Parties filed a complaint, subsequently amended, in Washoe County, Nevada against Arriva and numerous other parties alleging Arriva’s breach of the Protease License. (This action is hereinafter referred to as the “New Nevada Suit.”)

At the core of the New Nevada Suit is the Lezdey Parties’ claim that Arriva had a duty under the Protease License to record certain patents, defined as “Improvements” therein, in PSI’s name, and that Arriva failed to do so. Rather, allege the Lezdey Parties, Arriva registered the Improvements in its own name. The Lezdey Parties seek payments of damages and royalties, and other relief, in respect of the period following Arriva’s assumption of the Protease License.

The Lezdey Parties base their claims on Section 2.04 of the Licensing Agreement, which provides in relevant part that, “[Arrival hereby assigns to LICENSOR its entire irght [sic] title and interest in and to any IMPROVEMENTS ... The parties shall cooperate and act reasonably in seeking patent protection for IMPROVEMENTS.” See Arriva’s Request for Judicial Notice (“ARJN”), Doc. # 81, Ex. 1 at 23. Section 1.09 of the Protease License defines “Improvements” as “any inventions developed by [Arriva] or on its behalf during the term of this Agreement ... designed to be used to create products or processes in [PSI’s defined market application] and [ ] [that] entail the practice of one or more of [certain patents identified by the agreement].” Id. at 21-23.

In response, Arriva contends that the Lezdey Parties filed the New Nevada Suit in violation of the discharge injunction provided by Bankruptcy Code § 1141(b) 5 and (c) 6 , and Paragraph 19 of the Confirmation Order, 7 and that the Confirmation Order *423 barred the Lezdey Parties from asserting the aforementioned alleged breaches of the Protease License.

After the Lezdey Parties filed the New Nevada Suit, Arriva obtained an order reopening this chapter 11 bankruptcy case, and then filed the present adversary proceeding against the Lezdey Parties.

Now before this court is Arriva’s motion for summary judgment on its fourth claim for relief, in which Arriva argues that the Lezdey Parties are barred from bringing and prosecuting the New Nevada Suit. The court agrees, and will grant Arriva’s motion.

B. Discussion

1. Summary Judgment

Federal Rule of Civil Procedure 56, applicable herein via Federal Rule of Bankruptcy Procedure 7056, provides for summary judgment where “there is no genuine issue as to any material fact and ... the moving party is entitled to a judgment as a matter of law.” Fed.R.Civ.P. 56(c). “[A]t the summary judgment stage the judge’s function is not himself to weigh the evidence and determine the truth of the matter but to determine whether there is a genuine issue for trial.” Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 249, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986).

The court must view the facts in the light most favorable to the non-moving party. See County of Tuolumne v. Sonora Community Hosp., 236 F.3d 1148, 1154 (9th Cir.2001). The court will therefore assume, as the Lezdey Parties allege, that the patent applications at issue are properly characterized as Improvements under the Protease License, and that Arriva’s act of registering those patents in its own name was a breach by Arriva of the Protease License.

2. Arriva’s Assumption of the Protease License Created a Bar

Bankruptcy Code § 365(b) provides that a debtor in possession may not assume an executory contract if there has been a default, unless such default is cured at the time of assumption. 8 The cure re *424 quirement applies to both monetary and nonmonetary defaults (subject to certain exceptions, not relevant here, for executo-ry leases of real property).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
456 B.R. 419, 2011 WL 1577804, Counsel Stack Legal Research, https://law.counselstack.com/opinion/arriva-pharmaceuticals-inc-v-lezdey-in-re-arriva-pharmaceuticals-inc-canb-2011.